Carbognin, Luisa
 Distribuzione geografica
Continente #
EU - Europa 1.795
NA - Nord America 1.513
AS - Asia 1.102
SA - Sud America 134
AF - Africa 22
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.570
Nazione #
US - Stati Uniti d'America 1.490
RU - Federazione Russa 756
CN - Cina 431
SG - Singapore 383
GB - Regno Unito 361
SE - Svezia 130
IT - Italia 128
DE - Germania 121
BR - Brasile 101
HK - Hong Kong 101
IE - Irlanda 97
FR - Francia 83
VN - Vietnam 64
FI - Finlandia 46
KR - Corea 31
NL - Olanda 23
JP - Giappone 22
UA - Ucraina 17
IN - India 16
AR - Argentina 10
CA - Canada 8
MX - Messico 8
PL - Polonia 8
TR - Turchia 7
ZA - Sudafrica 7
EC - Ecuador 6
ID - Indonesia 6
UZ - Uzbekistan 6
BD - Bangladesh 5
MA - Marocco 5
PK - Pakistan 5
VE - Venezuela 5
ES - Italia 4
BJ - Benin 3
BO - Bolivia 3
IQ - Iraq 3
IR - Iran 3
PY - Paraguay 3
SA - Arabia Saudita 3
TG - Togo 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
AT - Austria 2
AU - Australia 2
BE - Belgio 2
CH - Svizzera 2
CL - Cile 2
CO - Colombia 2
DZ - Algeria 2
GR - Grecia 2
HN - Honduras 2
KZ - Kazakistan 2
LT - Lituania 2
NP - Nepal 2
PT - Portogallo 2
RO - Romania 2
TW - Taiwan 2
AL - Albania 1
AZ - Azerbaigian 1
CR - Costa Rica 1
EE - Estonia 1
EG - Egitto 1
EU - Europa 1
GA - Gabon 1
HT - Haiti 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
ME - Montenegro 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
TH - Thailandia 1
WS - Samoa 1
Totale 4.570
Città #
Southend 328
Chandler 263
Moscow 263
Singapore 152
Woodbridge 133
Dallas 125
Ashburn 102
Beijing 98
Hong Kong 98
Dublin 95
New York 75
Jacksonville 57
Munich 45
Ann Arbor 44
Los Angeles 39
Verona 32
Lawrence 31
Princeton 31
Ho Chi Minh City 30
Wilmington 28
Jinan 25
Shenyang 25
The Dalles 24
Nanjing 23
Seoul 22
Tianjin 21
Santa Clara 20
Turku 18
Tokyo 17
Columbus 15
Hanoi 15
Redondo Beach 15
Hebei 13
Houston 13
Buffalo 12
London 12
Zhengzhou 12
Chennai 11
Guangzhou 11
Sindelfingen 11
Changsha 10
Denver 10
Frankfurt am Main 8
Ningbo 8
Seattle 8
Mexico City 7
San Francisco 7
Stockholm 7
São Paulo 7
Amsterdam 6
Atlanta 6
Council Bluffs 6
Haikou 6
Hangzhou 6
Milan 6
Nanchang 6
Orem 6
Rome 6
Taiyuan 6
Tashkent 6
Brooklyn 5
Johannesburg 5
Markgröningen 5
Redmond 5
Redwood City 5
Augusta 4
Cagliari 4
Campo Grande 4
Dearborn 4
Helsinki 4
Lancaster 4
Meda 4
Shanghai 4
Taizhou 4
Warsaw 4
Biên Hòa 3
Bologna 3
Boston 3
Clearwater 3
Cotonou 3
Detroit 3
Fremont 3
Fuzhou 3
Guayaquil 3
Hải Dương 3
Istanbul 3
Jakarta 3
Jiaxing 3
Karachi 3
Kent 3
Lomé 3
Maceió 3
Manchester 3
Montreal 3
Mountain View 3
Phoenix 3
Poplar 3
Rio de Janeiro 3
Riva 3
San Mateo 3
Totale 2.682
Nome #
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 187
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 181
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 176
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 176
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 173
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 168
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 158
Identification of clinical, pathological and molecular predictors of prognosis in early-stage invasive lobular breast cancer: role of proliferation and CDK4/6 pathway. 158
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 156
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 152
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 146
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 145
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 138
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 134
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 132
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 132
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 131
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 129
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 128
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 128
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 126
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 120
Muscle derangement and alteration of the nutritional machinery in NSCLC 117
Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment 117
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 111
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 110
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 109
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 109
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 108
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? 104
Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success 93
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories 92
The obesity paradox in cancer: clinical insights and perspectives 88
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 85
Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. 79
Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story 42
Totale 4.638
Categoria #
all - tutte 16.424
article - articoli 15.504
book - libri 0
conference - conferenze 505
curatela - curatele 0
other - altro 415
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.848


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202191 0 0 0 0 24 19 2 2 7 5 26 6
2021/2022269 20 92 0 33 11 3 3 8 13 6 15 65
2022/2023645 36 90 39 134 57 151 3 37 64 1 20 13
2023/2024355 14 24 16 27 54 75 7 32 10 34 55 7
2024/2025812 38 33 44 158 26 38 16 20 138 56 86 159
2025/20261.525 178 103 150 452 642 0 0 0 0 0 0 0
Totale 4.638